Ultragenyx shares surged 5.2% in the last trading session to close at $30.77, driven by higher-than-usual trading volume. The stock has gained 25.8% over the past four weeks, fueled by investor optimism around its growing portfolio of marketed rare disease therapies and a promising late-stage pipeline. Key products Crysvita, Dojolvi, and Mepsevii continue to drive revenue growth, while upcoming catalysts include an FDA decision on DTX401 for glycogen storage disease type Ia expected in August 2026, positive late-stage data for DTX301 in OTC deficiency, and readouts for UX701 in Wilson disease and GTX-102 in Angelman syndrome in 2026. The company is expected to report a quarterly loss of $1.25 per share on revenues of $185.77 million. Analysts have kept consensus estimates unchanged over the past 30 days, and the stock carries a Zacks Rank of 3, or Hold.
UltragenyxPipeline optimism driven by upcoming FDA decision and late-stage data readouts for multiple therapies.
Tarsus Pharmaceuticals Inc